Monday 01/11/2010 9:02 AM ET - GlobeNewswire

Wednesday 01/13/2010 9:30 AM ET - GlobeNewswire

Excerpt: "Generex has positioned itself to be the next target of high-risk, high-reward investors and institutions, as this upcoming year will prove to be the climax for the company," notes Michael Vlaicu of TheMarketFinancial. "With the recent contracting news regarding 7000 stores, and an initial $800,000 order for company's proprietary Crave-NX(TM) 7-Day Diet Aid Spra., a viable reoccurring revenue stream will now be present, thus paving the way for a much improved balance sheet on the eve of Oral-Lyn's NDA application and the beginning of AE37's Breast Cancer Immunotherapy Phase III trials, both of which are expected to take place sometime in Q3 or Q4 of this year."

Approval upon NDA submission is highly anticipated for Oral-Lyn (Type 1, Type 2 Diabetes oral insulin spray treatment) due to the fact that it has been accepted to be a part of USFDA's Treatment Investigational New Drug program. "Companies like Dendreon Corporation, Human Genome Sciences, and MannKind Corporation went from relatively unknown to being dominant market players, and Generex (NASDAQ: GNBT) has all the makings to be next in line."

Last Trade: 0.70 Trade Time: 1:01PM ET Change: 0.01 (0.74%) Prev Close: 0.69 Open: 0.71 Bid: 0.69 x 3700 Ask: 0.70 x 1200 1y Target Est: 6.00

Day's Range: 0.69 - 0.73 52wk Range: 0.08 - 1.14 Volume: 4,897,968 Avg Vol (3m): 3,217,190 Market Cap: 172.75M

Company	Market Cap	YTD Price Performance
GNBT Generex Biotechnology Corp	171.5M	+30.2%

Balance sheet not bad, in terms of cash / debt.

Balance Sheet
Total Cash (mrq):	26.26M
Total Cash Per Share (mrq):	0.106
Total Debt (mrq):	2.97M
Total Debt/Equity (mrq):	N/A
Current Ratio (mrq):	3.197
Book Value Per Share (mrq):	0.107

One concern however is the float:

Shares Outstanding5:	248.52M
Float:	242.81M

Regarding insider action, nice to note a string of insider purchases in the last qtr.

The last GNBT insider buy occurred when FLETCHER MARK purchased a total of 8,700 shares on 1/4/2010. His total share holdings are now 266,077.Mark is Executive VP and General Counsel. In the last 5 years insiders have on average purchased 39,032 shares each year. A nice little vote of confidence into the new year.

INSIDER TRANSACTIONS REPORTED - LAST TWO YEARS

Date Insider Shares Type Transaction Value* 4-Jan-10 FLETCHER MARK Officer 8,700 Direct Purchase at $0.52 per share. $4,524 16-Nov-09 PERRI ROSE C Officer 10,000 Direct Purchase at $0.51 per share. $5,100 13-Nov-09 FLETCHER MARK Officer 10,000 Direct Purchase at $0.49 per share. $4,900 13-Nov-09 MASTERSON NOLA E Director 10,000 Direct Purchase at $0.49 per share. $4,900

Regarding coverage,

Reuters has them listed as an outperform. The link below provides a very detailed breakdown on their stats. The report is recent also: 11 Jan 2010

http://www.stockcast.info/images/fbfiles/files/file-57a4012e65accd246fc704f70ff8cd32.pdf

A board thead of interest:

GNBT is fine folks, remember- development stage co...
by neveraloss... [14-Jan-10 10:03 am]

....GNBT already has OTC products on the market, is developing multiple drugs including Oralyn, AE/37, Metaformin gum, OTC, flu vaccine, prostate vaccine....etc etc.

Once GNBT catches fire the uptrend will be drastic, and significant.....

Something else to point out. MNKD is rallying strong today on drug approval anticipation. GNBT is in a similiar mkt.

10.13

1.23

13.82%

3,826,326

Last Trade as of 2:27 PM ET 1/14/10

A related thread:

Folks, this is a good thing for GNBT. If MNKD approved, then we are a shoe in. GNBT will rally.

Contact Info

Generex Biotechnology Corporation

33 Harbour Square, Suite 202, Toronto, ON,

M5J 2G2 Canada

(416) 364-2551

www.generex.com/

Ms. Anna E. Gluskin , 59
Chairperson, Chief Exec. Officer and Pres

Generex Biotechnology engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company?s products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation?s under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum. The company was founded in 1983 and is based in Toronto, Canada.